Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis

NCT ID: NCT07187895

Last Updated: 2026-01-12

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 17 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-12-19
• Study Completion Date: 2025-03-05

Brief Summary

Compare the diagnostic certainty of MIBI SPECT myocardial perfusion imaging (MPI) and XTR004 PET MPI.

Detailed Description

This trial is a single-arm, single-center, open-label, self-controlled study. Patients with suspected or known stable coronary artery disease who have previously undergone coronary CTA showing 30%-80% stenosis in any coronary vessel, or mild to moderate stenosis, will be enrolled and sequentially undergo MIBI SPECT myocardial perfusion imaging (MPI) and XTR004 PET MPI. Imaging will be independently and blindly read by expert readers for both MIBI SPECT MPI and XTR004 PET MPI. The diagnostic certainty of the reading results from the two imaging modalities will then be compared.

Conditions

Myocardial Perfusion Imaging; Diagnostic Certainty; Stable Coronary Artery Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

XTR004 MPI PET & MIBI SPECT MPI

Patients with suspected or known stable coronary artery disease who have previously undergone coronary CTA showing 30%-80% stenosis in any coronary vessel, or mild to moderate stenosis, will be enrolled and sequentially undergo MIBI SPECT myocardial perfusion imaging (MPI) and XTR004 PET MPI

Group Type: EXPERIMENTAL

XTR004

Intervention Type: DRUG

At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi

At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi.

Interventions

XTR004

At rest: IV bolus injection of XTR004 with a dose range of 2.0-2.5 mCi

At stress: IV infusion of adenosine at a rate of 140 μg/kg/min. IV bolus injection of XTR004 with a dose range of 6.0-7.5 mCi.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 1.Male or female participants aged 18 years or older.
• 2.Suspected or known stable coronary artery disease with related symptoms and stable condition, and having at least one coronary artery disease risk factor, including: hypertension, hyperlipidemia, diabetes, obesity, alcohol abuse, smoking, family history of coronary artery disease, postmenopausal status in women, or advanced age.
• 3.Underwent coronary CTA within the past 6 months showing 30%-90% stenosis, or indicating mild to moderate-to-severe stenosis.
• 4.Able to communicate effectively with the investigators, understand and comply with the clinical study requirements, voluntarily participate in the study, and provide written informed consent.

Exclusion Criteria

• 1. Patients with a history of percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).
• 2.Patients with a prior diagnosis of myocardial infarction, congenital heart disease, cardiomyopathy, myocarditis, or other cardiac diseases.
• 3.Patients known to have severe allergic reactions to alcohol.
• 4.Patients known to have an allergy or other contraindications to adenosine.
• 5.Patients known to be allergic to iodinated contrast agents.
• 6.Individuals with significant occupational exposure to ionizing radiation within the past 10 years (e.g., exceeding 50 mSv/year), or exposure to radioactive substances or ionizing radiation for therapeutic or research purposes.
• 7.Men and women of childbearing potential who do not plan to use effective contraception during the study and for 6 months after study completion (effective methods include sterilization, intrauterine hormonal devices, condoms, contraceptive pills/agents, abstinence, or partner vasectomy/tubal ligation).
• 8.Pregnant or lactating women.
• 9.Patients with claustrophobia, bipolar disorder, other psychiatric disorders, or poor compliance.
• 10.Patients who participated in another investigational drug clinical study within 30 days prior to enrollment or plan to do so during follow-up.
• 11.Any other condition that, in the opinion of the investigators, makes the patient unsuitable for participation.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sinotau Pharmaceutical Group

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Fuwai Hospital

Beijing, Beijing Municipality, China

Countries

China

Other Identifiers

STB-XTR004-202

Identifier Type: -

Identifier Source: org_study_id